Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:20 AM
Ignite Modification Date:
2025-12-25 @ 12:20 AM
NCT ID:
NCT00860158
Brief Summary:
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
Detailed Description:
OUTLINE: This is a multi-center study.
* Dasatinib -100 mg administered once daily per oral route for 28 consecutive days.
* Leuprolide acetate - 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
The 28 days of dasatinib and leuprolide injection (plus the time required to recover from toxicity if encountered) is defined as a cycle. Patients will be treated for up to a maximum of 3 cycles of dasatinib and leuprolide acetate.
Radical Prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Hematopoietic:
* Hemoglobin (Hgb) ≥ 8.0 g/dL
* Platelets ≥ 100 K/mm3
* Absolute neutrophil count (ANC) ≥ 1.0 K/mm3
Hepatic:
* Total bilirubin \< 2.0 X Upper Limit Normal (ULN)
* Aspartate aminotransferase (AST) \< 2.5 X ULN
* Alanine aminotransferase (ALT) \< 2.5 X ULN
Renal:
* Calculated creatinine clearance of ≥ 60 cc/min using the Cockcroft-Gault formula
Cardiovascular:
* No uncontrolled angina, congestive heart failure or myocardial infarction within 6 months prior to registration for protocol therapy.
Study:
NCT00860158
Study Brief:
Protocol Section:
NCT00860158